X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-05-06 | ROIV | Roivant Sciences Ltd. | Ramaswamy Vivek | 10% | S - Sale | $11.27 | -898,959 | 52,532,468 | -2% | -$10,129,810 | |||||
| D | 2025-05-06 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $74.31 | -7,060 | 5,487 | -56% | -$524,653 | |||||
| D | 2025-05-06 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale+OE | $43.43 | -12,500 | 169,721 | -7% | -$542,864 | |||||
| M | 2025-05-06 | PHAT | Phathom Pharmaceuticals, Inc. | Parikh Asit | Dir | P - Purchase | $2.50 | +10,000 | 95,500 | +12% | +$24,985 | |||||
2025-05-06 | VRNA | Verona Pharma Plc | Rickard Kathleen A. | Chief Medical Officer | S - Sale | $8.82 | -114,984 | 2,546,472 | -4% | -$1,014,343 | ||||||
| D | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Chief Scientific Officer | S - Sale+OE | $16.45 | -1,551 | 18,521 | -8% | -$25,520 | |||||
| D | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | Moore John R | GC | S - Sale+OE | $16.45 | -1,930 | 6,531 | -23% | -$31,757 | |||||
| D | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | Koch Kevin | Pres, CEO | S - Sale+OE | $16.45 | -4,276 | 385,813 | -1% | -$70,358 | |||||
| D | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $16.45 | -5,187 | 21,588 | -19% | -$85,348 | |||||
| M | 2025-05-05 | LFCR | Lifecore Biomedical, Inc. De | English Aron R. | 10% | S - Sale | $7.05 | -41,091 | 1,714,070 | -2% | -$289,869 | |||||
| D | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | Derakhshan Behrad | Chief Business Officer | S - Sale+OE | $16.45 | -1,691 | 20,355 | -8% | -$27,824 | |||||
| D | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | Carruthers R Michael | CFO | S - Sale+OE | $16.45 | -1,314 | 81,014 | -2% | -$21,621 | |||||
2025-05-06 | KPTI | Karyopharm Therapeutics Inc. | Paulson Richard A. | Pres, CEO | S - Sale | $7.12 | -236 | 82,503 | 0% | -$1,680 | ||||||
2025-05-05 | BPMC | Blueprint Medicines Corp | Rossi Christina | COO | S - Sale | $101.75 | -2,274 | 66,992 | -3% | -$231,386 | ||||||
| D | 2025-05-05 | BPMC | Blueprint Medicines Corp | Hurley Ariel | Principal Accounting Officer | S - Sale+OE | $103.13 | -2,752 | 16,944 | -14% | -$283,819 | |||||
2025-05-05 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $7.30 | -820 | 345,659 | 0% | -$5,986 | ||||||
2025-05-07 | OGN | Organon & Co. | Falcione Aaron | CHRO | P - Purchase | $8.77 | +5,500 | 62,974 | +10% | +$48,235 | ||||||
2025-05-06 | OGN | Organon & Co. | Weaver Kirke | Gen. Counsel, Corp. Secy. | P - Purchase | $9.21 | +8,045 | 52,489 | +18% | +$74,054 | ||||||
2025-05-06 | OGN | Organon & Co. | Karp Daniel | EVP, Corp. Dev. | P - Purchase | $8.24 | +3,500 | 46,669 | +8% | +$28,828 | ||||||
| AD | 2024-09-24 | ERNA | Ernexa Therapeutics Inc. | Cherington Charles | 10% | P - Purchase | $0.00 | +13,252,112 | 13,808,577 | >999% | +$0 | |||||
| M | 2025-05-02 | ALMS | Alumis Inc. | Tananbaum James B. | Dir, 10% | P - Purchase | $4.50 | +45,000 | 15,197,954 | 0% | +$202,300 | |||||
| M | 2025-05-02 | ALMS | Alumis Inc. | Foresite Labs, LLC | 10% | P - Purchase | $4.50 | +45,000 | 15,197,954 | 0% | +$202,300 | |||||
| M | 2025-05-02 | ALMS | Alumis Inc. | Foresite Capital Management VI LLC | 10% | P - Purchase | $4.50 | +45,000 | 15,197,954 | 0% | +$202,300 | |||||
2025-05-02 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale | $50.17 | -2,100 | 66,398 | -3% | -$105,367 | ||||||
| M | 2025-05-02 | PRTA | Prothena Corp Public Ltd Co | Ecor1 Capital, LLC | 10% | S - Sale | $8.10 | -6,279,684 | 5,304,596 | -54% | -$50,839,807 | |||||
| M | 2025-05-02 | ALMS | Alumis Inc. | Akkaraju Srinivas | Dir | P - Purchase | $4.61 | +320,290 | 3,586,788 | +10% | +$1,477,312 | |||||
2025-05-02 | BMRN | Biomarin Pharmaceutical Inc | Hubbard Cristin | EVP, Chief Commercial Officer | S - Sale | $64.92 | -273 | 32,700 | -1% | -$17,723 | ||||||
2025-05-02 | BBIO | Bridgebio Pharma, Inc. | Apuli Maricel | Chief Accounting Officer | S - Sale | $38.51 | -1,026 | 147,639 | -1% | -$39,509 | ||||||
2025-05-02 | BBIO | Bridgebio Pharma, Inc. | Lo Andrew | Dir | S - Sale | $38.50 | -100,000 | 153,682 | -39% | -$3,849,900 | ||||||
2025-05-02 | XNCR | Xencor Inc | Valente Nancy | EVP, Chief Development Officer | S - Sale | $11.03 | -4,616 | 49,169 | -9% | -$50,914 | ||||||
| D | 2025-05-06 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $35.01 | -2,000 | 140,255 | -1% | -$70,020 | |||||
| M | 2025-05-02 | AMRX | Amneal Pharmaceuticals, Inc. | Patel Gautam | Dir | S - Sale | $8.00 | -8,668 | 1,720,218 | -1% | -$69,344 | |||||
| D | 2025-05-02 | NUVB | Nuvation Bio Inc. | Liu Dongfang | Chief Medical Officer | S - Sale+OE | $2.50 | -20,000 | 12,000 | -63% | -$50,024 | |||||
2025-05-05 | OGN | Organon & Co. | Walsh Matthew M | CFO | P - Purchase | $8.82 | +11,400 | 144,484 | +9% | +$100,548 | ||||||
2025-05-05 | OGN | Organon & Co. | Ali Kevin | CEO | P - Purchase | $8.81 | +34,000 | 282,731 | +14% | +$299,370 | ||||||
| D | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale+OE | $21.05 | -1,784 | 93,126 | -2% | -$37,553 | |||||
| D | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO | S - Sale+OE | $21.05 | -18,924 | 419,173 | -4% | -$398,350 | |||||
| D | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Chief Commercial Officer | S - Sale+OE | $21.05 | -1,771 | 128,215 | -1% | -$37,280 | |||||
| D | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | Rote William E. | Chief Research Officer | S - Sale+OE | $21.05 | -3,198 | 100,241 | -3% | -$67,318 | |||||
| D | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | GC, GC | S - Sale+OE | $21.05 | -4,920 | 89,482 | -5% | -$103,566 | |||||
| DM | 2024-12-16 | BOLT | Bolt Biotherapeutics, Inc. | Nemec Sarah | SVP, Finance, PAO | P - Purchase | $0.57 | +5,000 | 13,863 | +56% | +$2,835 | |||||
| DM | 2024-12-16 | BOLT | Bolt Biotherapeutics, Inc. | Quinn William P. | Pres, CEO, CFO | P - Purchase | $0.57 | +5,000 | 38,772 | +15% | +$2,835 | |||||
| DM | 2025-05-01 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $72.13 | -39,410 | 105,622 | -27% | -$2,842,769 | |||||
2025-05-02 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $72.90 | -40,000 | 2,941,985 | -1% | -$2,915,922 | ||||||
| D | 2025-05-01 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $71.96 | -9,350 | 9,009 | -51% | -$672,781 | |||||
2025-05-02 | ARDX | Ardelyx, Inc. | Mott David M | Dir | P - Purchase | $4.22 | +381,377 | 2,396,871 | +19% | +$1,610,936 | ||||||
| D | 2025-05-02 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale+OE | $4.25 | -41,666 | 1,620,118 | -3% | -$177,168 | |||||
| M | 2025-04-21 | RARE | Ultragenyx Pharmaceutical Inc. | Crombez Eric | EVP, Chief Medical Officer | S - Sale | $37.93 | -762 | 71,530 | -1% | -$28,901 | |||||
| M | 2025-05-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | COB, CEO | S - Sale | $117.57 | -1,500 | 438,807 | 0% | -$176,350 | |||||
| M | 2025-05-01 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $20.05 | -7,500 | 990,188 | -1% | -$150,391 | |||||
| M | 2025-05-01 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale | $20.06 | -7,500 | 977,892 | -1% | -$150,415 | |||||
2025-05-05 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $36.68 | -4,002 | 60,687 | -6% | -$146,793 | ||||||
2025-05-02 | DERM | Journey Medical Corp | Maraoui Claude | Pres, CEO | S - Sale | $6.84 | -4,834 | 2,348,313 | 0% | -$33,065 | ||||||
2025-05-02 | DERM | Journey Medical Corp | Benesch Joseph | CFO | S - Sale | $6.84 | -2,409 | 203,557 | -1% | -$16,478 | ||||||
2025-05-02 | DERM | Journey Medical Corp | Alloush Ramsey | COO | S - Sale | $6.84 | -2,857 | 504,817 | -1% | -$19,542 | ||||||
2025-05-02 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $15.20 | -5,030 | 204,399 | -2% | -$76,453 | ||||||
2025-05-02 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd Franklin | See Remarks | S - Sale | $15.19 | -11,448 | 1,144,935 | -1% | -$173,917 | ||||||
2025-05-02 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale | $15.19 | -2,597 | 119,339 | -2% | -$39,442 | ||||||
| DM | 2025-05-02 | KNSA | Kiniksa Pharmaceuticals International, Plc | Moat Ross | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $28.00 | -10,122 | 9,415 | -52% | -$283,416 | |||||
2025-05-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale | $14.64 | -10,000 | 111,944 | -8% | -$146,357 | ||||||
| D | 2025-05-01 | VRNA | Verona Pharma Plc | Rickard Kathleen A. | Chief Medical Officer | S - Sale+OE | $8.95 | -49,200 | 2,661,456 | -2% | -$440,350 | |||||
| DM | 2025-05-01 | VRNA | Verona Pharma Plc | Hahn Mark W | CFO | S - Sale+OE | $9.05 | -587,008 | 13,078,992 | -4% | -$5,311,479 | |||||
| DM | 2025-05-01 | VRNA | Verona Pharma Plc | Zaccardelli David | Pres, CEO | S - Sale+OE | $9.05 | -587,008 | 13,990,168 | -4% | -$5,311,279 | |||||
2025-05-02 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bhatia Sangeeta N. | Dir | S - Sale | $505.86 | -400 | 4,831 | -8% | -$202,344 | ||||||
| M | 2025-05-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $10.02 | -26,631 | 33,998 | -44% | -$266,953 | |||||
2025-05-01 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale | $24.08 | -500 | 73,409 | -1% | -$12,041 | ||||||
| D | 2025-05-02 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale+OE | $14.60 | -1,327 | 23,526 | -5% | -$19,374 | |||||
| D | 2025-05-01 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Officer | S - Sale+OE | $32.03 | -3,333 | 82,139 | -4% | -$106,745 | |||||
| D | 2025-05-02 | ACAD | Acadia Pharmaceuticals Inc | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $14.60 | -3,498 | 62,773 | -5% | -$51,071 | |||||
| D | 2025-05-01 | RNA | Avidity Biosciences, Inc. | Gallagher Kathleen P. | Chief Program Officer | S - Sale+OE | $32.40 | -5,875 | 50,554 | -10% | -$190,324 | |||||
2025-05-02 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale | $11.33 | -6,198 | 33,724 | -16% | -$70,243 | ||||||
2025-04-30 | ABT | Abbott Laboratories | Blount Sally E. | Dir | S - Sale | $129.66 | -2,600 | 34,058 | -7% | -$337,116 | ||||||
| D | 2025-05-01 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $72.57 | -6,830 | 618,610 | -1% | -$495,668 | |||||
2025-05-01 | IONS | Ionis Pharmaceuticals Inc | Hayden Michael R | Dir | P - Purchase | $31.86 | +15,000 | 52,219 | +40% | +$477,900 | ||||||
| D | 2025-05-01 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $300.93 | -11,000 | 36,781 | -23% | -$3,310,201 | |||||
| D | 2025-05-01 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $14.00 | -311 | 110,886 | 0% | -$4,354 | |||||
| M | 2024-12-18 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $13.26 | +207,436 | 926,943 | +29% | +$2,749,916 | |||||
| D | 2025-04-29 | VRNA | Verona Pharma Plc | Fisher Andrew | GC | S - Sale+OE | $8.98 | -26,072 | 359,993 | -7% | -$234,127 | |||||
| D | 2025-04-29 | VRNA | Verona Pharma Plc | Zaccardelli David | Pres, CEO | S - Sale+OE | $8.98 | -90,360 | 14,377,176 | -1% | -$811,433 | |||||
| D | 2025-04-29 | VRNA | Verona Pharma Plc | Rickard Kathleen A. | Chief Medical Officer | S - Sale+OE | $8.98 | -34,384 | 2,660,656 | -1% | -$308,768 | |||||
| D | 2025-04-29 | VRNA | Verona Pharma Plc | Hahn Mark W | CFO | S - Sale+OE | $8.98 | -90,360 | 13,466,000 | -1% | -$811,433 | |||||
| D | 2025-04-29 | VRNA | Verona Pharma Plc | Sinha Vikas | Dir | S - Sale+OE | $8.92 | -20,000 | 74,440 | -21% | -$178,416 | |||||
| M | 2025-04-30 | ACRV | Acrivon Therapeutics, Inc. | Perceptive Advisors LLC | 10% | S - Sale | $1.38 | -736,767 | 3,104,139 | -19% | -$1,017,919 | |||||
| DM | 2025-04-29 | KNSA | Kiniksa Pharmaceuticals International, Plc | Moat Ross | CHIEF COMMERCIAL OFFICER | S - Sale+OE | $25.96 | -87,269 | 9,415 | -90% | -$2,265,339 | |||||
| DM | 2025-04-29 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale+OE | $26.56 | -88,395 | 27,009 | -77% | -$2,347,335 | |||||
| D | 2025-04-29 | RYTM | Rhythm Pharmaceuticals, Inc. | Cramer Pamela J. | CHRO | S - Sale+OE | $65.09 | -7,031 | 19,209 | -27% | -$457,663 | |||||
2025-04-29 | RYTM | Rhythm Pharmaceuticals, Inc. | Mazabraud Yann | EVP, Head of International | S - Sale | $65.08 | -6,745 | 37,655 | -15% | -$438,946 | ||||||
| D | 2025-04-29 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $74.56 | -4,000 | 48,034 | -8% | -$298,240 | |||||
| D | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $11.50 | -3,377 | 61,516 | -5% | -$38,841 | |||||
| D | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $11.50 | -2,894 | 37,318 | -7% | -$33,286 | |||||
| D | 2025-04-30 | NRIX | Nurix Therapeutics, Inc. | Van Houte Hans | CFO | S - Sale+OE | $11.50 | -2,438 | 39,922 | -6% | -$28,041 | |||||
| D | 2025-04-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $18.69 | -3,250 | 23,000 | -12% | -$60,738 | |||||
2025-04-30 | ZNTL | Zentalis Pharmaceuticals, Inc. | Myers Scott Dunseth | Dir | P - Purchase | $1.40 | +21,000 | 281,192 | +8% | +$29,373 | ||||||
| D | 2025-03-27 | HOWL | Werewolf Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale+OE | $1.05 | -1,963 | 3,208,793 | 0% | -$2,061 | |||||
2025-04-28 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale | $14.24 | -455 | 183,849 | 0% | -$6,479 | ||||||
| D | 2025-03-27 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir, 10% | S - Sale+OE | $1.05 | -2,425 | 4,309,860 | 0% | -$2,546 | |||||
| D | 2025-03-27 | HOWL | Werewolf Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale+OE | $1.05 | -4,386 | 6,718,670 | 0% | -$4,605 | |||||
| M | 2025-04-25 | ACRV | Acrivon Therapeutics, Inc. | Perceptive Advisors LLC | 10% | S - Sale | $1.81 | -1,519,952 | 3,840,906 | -28% | -$2,744,946 | |||||
2025-04-25 | BMY | Bristol Myers Squibb Co | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | P - Purchase | $47.58 | +4,250 | 83,513 | +5% | +$202,215 | ||||||
| DM | 2025-04-25 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $14.00 | -5,689 | 110,886 | -5% | -$79,658 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |